Zai Lab Ltd
ZLAB
View Detailed Chart
32.650USD
-0.350-1.06%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
3.59BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.06%
5 Days
-0.46%
1 Month
-7.87%
6 Months
-14.10%
Year to Date
+24.67%
1 Year
+54.81%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Buy
Current Rating
55.899
Target Price
+69.39%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 85.54% year-on-year.
Undervalued
The company’s latest PE is -15.95, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 60.58M shares, decreasing 16.48% quarter-over-quarter.
Held by Ron Baron
Star Investor Ron Baron holds 1.59M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.33.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Ticker SymbolZLAB
CompanyZai Lab Ltd
CEODr. Ying (Samantha) Du, Ph.D.
Websitehttps://www.zailaboratory.com/
Related Instruments
-1.43%
+1.17%
+0.22%
+0.52%
-1.03%
-0.73%
-0.02%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.27%
+1.19%
+0.92%
-0.87%
-0.23%
-0.83%
-1.12%
+0.31%
